# Phase II Evaluation of AHCC for the Eradication of HPV Infections

> **NCT02405533** · NA · COMPLETED · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 50 (actual)

## Conditions studied

- Human Papilloma Virus
- Dysplasia
- CIN1
- CIN2

## Interventions

- **DIETARY_SUPPLEMENT:** AHCC 3 grams once a day
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02405533
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2019-11
- **Final completion:** 2019-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02405533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02405533, "Phase II Evaluation of AHCC for the Eradication of HPV Infections". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02405533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*